Regeneron Pharmaceuticals Inc (REGN)
NASDAQ · Healthcare · Biotechnology
Regeneron Pharmaceuticals Inc is a Healthcare company with a market capitalization of $66.35B, a trailing P/E ratio of 15.5, and a dividend yield of 0.58%.
5-Year Price History
Latest Annual Financials · FY ending December 31, 2025
Recent Quarterly Earnings (EPS)
| Quarter | Reported | Actual EPS | Estimate | Surprise |
|---|---|---|---|---|
| Q1 2026 | April 29, 2026 | $9.47 | $8.90 | +6.4% |
| Q4 2025 | January 30, 2026 | $11.44 | $10.75 | +6.4% |
| Q3 2025 | October 28, 2025 | $11.83 | $9.64 | +22.7% |
| Q2 2025 | August 1, 2025 | $12.89 | $8.44 | +52.7% |
| Q1 2025 | April 29, 2025 | $8.22 | $8.48 | -3.1% |
| Q4 2024 | February 4, 2025 | $12.07 | $11.19 | +7.9% |
Other Biotechnology Stocks
Frequently Asked Questions
What is Regeneron Pharmaceuticals Inc's market cap?
As of June 29, 2026, Regeneron Pharmaceuticals Inc (REGN) has a market capitalization of $66.35B.
What is Regeneron Pharmaceuticals Inc's P/E ratio?
Regeneron Pharmaceuticals Inc trades at a trailing price-to-earnings (P/E) ratio of 15.5. Its forward P/E is 14.1.
Does Regeneron Pharmaceuticals Inc pay a dividend?
Yes — Regeneron Pharmaceuticals Inc pays a dividend yielding 0.58%, an annual payout of $3.58 per share.
What sector is REGN in?
Regeneron Pharmaceuticals Inc is in the Healthcare sector, specifically the Biotechnology industry.
What was Regeneron Pharmaceuticals Inc's revenue?
In its latest reported fiscal year (ending December 31, 2025), Regeneron Pharmaceuticals Inc reported revenue of $14.34B and net income of $4.50B.
Ask your own questions about REGN
Try mrmarket.ai freeData as of June 29, 2026. Figures are sourced from company filings and market data and may be delayed or revised. For informational purposes only — not investment advice.